Paroxetine
- Generic Name
- Paroxetine
- Brand Names
- Paxil, Pexeva
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20FNO3
- CAS Number
- 61869-08-7
- Unique Ingredient Identifier
- 41VRH5220H
- Background
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...
- Indication
Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...
- Associated Conditions
- Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Paroxetine Safety and Efficacy in Rheumatoid Arthritis
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Mostafa Bahaa
- Target Recruit Count
- 100
- Registration Number
- NCT06231745
- Locations
- 🇪🇬
Mostafa Bahaa, Damietta, New Damietta, Egypt
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Asceneuron S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06232109
- Locations
- 🇳🇱
ICON Groningen Van Swietenlaan 6, Groningen, Netherlands
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- aya ramadan ashmawy sarhan
- Target Recruit Count
- 44
- Registration Number
- NCT06203275
Concentration-QT Study of Paroxetine in Healthy Adults
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT06065735
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
Effects of Paroxetine on Cardiovascular Function in Septic Patients
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 92
- Registration Number
- NCT05725837
- Locations
- 🇧🇷
Hospital São José, Criciúma, Santa Catarina, Brazil
🇧🇷Hospital Maternidade São José de Colatina, Colatina, Espirito Santo, Brazil
EEG Results of Deep TMS in Patients With OCD
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Istanbul Medipol University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05188833
- Locations
- 🇹🇷
Istanbul Medipol University, Istanbul, Beykoz, Turkey
Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 24
- Registration Number
- NCT05175430
- Locations
- 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04981704
- Locations
- 🇺🇸
Celerion, Phoenix clinical facility, Tempe, Arizona, United States
To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 24
- Registration Number
- NCT04888728
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.